Results 261 to 270 of about 7,559,498 (434)

The nuclear receptor superfamily: The second decade

open access: yesCell, 1995
D. Mangelsdorf   +10 more
semanticscholar   +1 more source

TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis

open access: yesMolecular Oncology, EarlyView.
TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam   +9 more
wiley   +1 more source

Enhancing patient engagement in cancer research: a focus on patient‐centric approaches to scientific discovery

open access: yesMolecular Oncology, EarlyView.
Patient engagement involves actively including patients in healthcare decisions and research to ensure care and studies align with their needs. This approach improves outcomes, trust, and communication while fostering collaboration between patients and professionals.
Estela Cepeda   +3 more
wiley   +1 more source

Androgens as the "old age stick" in skeletal muscle. [PDF]

open access: yesCell Commun Signal
Giulia G   +8 more
europepmc   +1 more source

Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy